Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic intensification with raltegravir with or without maraviroc in chronic HIV-1 infection
2009-014602-33Phase 3Active
- Sponsor
- Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of raltegravir and aprepitant in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Centre Hospitalier Intercommunal de Toulon-La Seyne-sur-Mer. Primary endpoint: Residual plasma viral replication. Started Oct 2009; status: active.
02
Drugs
raltegraviraprepitant
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-014602-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014602-33.